Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Summary

Pilot, single center, open-label study to evaluate the efficacy and tolerability of Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant recipients with hepatitis C recurrence.

Timeline

Start

2016-08-03

Primary completion

2017-06-01

Completion

2017-06-01

Outcome

Outcome not reported

Stopped: “Impossibility of supplying the medication in research of the study by the pharmaceutical company that gave it to the trial”

Drugs

Indications